Browsed by
Month: March 2019

Oncolytic virotherapy [3]

Oncolytic virotherapy [3]

Monotherapy with oncolytic viruses Current research on viruses indicates that malignant cell death can be caused by nearly every virus and in almost all types of tumours. The first of these studies was conducted at the end of the 1940s by Alice Moore who was the first scientist to prove that viruses had innate oncolytic properties. She did so by prescribing them to patients with a variety of different malignant tumours. In recent years, the range of studied viruses has…

Read More Read More

Oncolytic virotherapy [2]

Oncolytic virotherapy [2]

The effect of oncolytic viruses on the immune system Scientists began studying the impact of oncolytic viruses on the immune system in the 1960s. An oncolytic virus-induced immune response against tumours after active viral replication is now considered to be the main requirement for a successful treatment. Patients who experience an improved immune system response as a result of oncolytic virotherapy are considered to be elite responders. They can also expect the longest periods of disease regression. Therefore, in the…

Read More Read More